Pipeline

April 5, 2020

Company	Drug/Device	Medical Condition	Status
COVID-19 Trials
World Health Organization	chloroquine and hydroxychloroquine, Remdesivir, a combination of HIV drugs Lopinavir and Ritonavir and a combination of those drugs plus interferon-beta	coronavirus (COVID-19)	clinical trial initiated
Riovant	gimsilumab	SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS)	completion of phase 1 trial
Apeiron Biologics AG	APN01	severely infected COVID-19 patients	initiation of phase 2 trial
Sanofi Regeneron	Kevzara (sarilumab)	patients hospitalized with severe COVID-19	initiation of second phase 2/3 trial
Other Trials
Zymeworks BeiGene	ZW25 in combination with chemotherapy and tislelizumab	first-line treatment for patients with metastatic HER2-positive breast cancer and metastatic HER2-positive gastroesophageal adenocarcinoma	first patient dosed in phase 1b/2 trial
InMed Pharmaceuticals	INM-755 cream	epidermolysis bullosa	completion of phase 1 trial
Chi-Med	HMPL-453	advanced malignant mesothelioma	initiation of phase 2 trial
Mimetogen Pharmaceuticals	tavilermide	dry eye disease	completed enrollment in phase 3 trial
Onconova Therapeutics	rigosertib	patients with higher-risk myelodysplastic syndromes (MDS) who have progressed on, failed to respond to or relapsed after prior hypomethylating agent (HMA) therapy	completion of patient enrollment in phase 3 trial
Oyster Point Therapeutics	OC-01 nasal spray	signs and symptoms of dry eye disease	completed enrollment in phase 3 trial
Seres Therapeutics	SER-109	recurrent Clostridium difficile infection	completed enrollment in phase 3 trial
MEI Pharma	ME-401	adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies	Fast-Track designation granted by FDA
Ryvu Therapeutics	SEL120	acute myeloid leukemia	Orphan Drug designation granted by FDA
Agios Pharmaceuticals	AG-946	hemolytic anemias	IND approved by the FDA
AnHeart Therapeutics	taletrectinib	first-and second-line Non-Small Cell Lung Cancer (NSCLC) patients with ROS1 mutations and locally advanced or metastatic solid tumors with NTRK mutations	IND clearance and Clinical Trial Authorization granted from Chinese drug evaluation agency (CDE)
Intellia Therapeutics Novartis	CRISPR/Cas9-based engineered cell therapy	sickle cell disease	IND approved by FDA
Chipscreen Biosciences	CS12192	autoimmune diseases and other related diseases	IND approved by Center for Drug Evaluation, National Medical Products Administration of China
AstraZeneca	Imfinzi (durvalumab)	first-line treatment for adult patients with extensive-stage small cell lung cancer in combination with standard-of-care chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide)	approved by the FDA
Eli Lilly	Taltz (ixekizumab) injection	pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy	approved by the FDA for expanded indication
Rockwell Medical	intravenous formulation of Triferic (Triferic AVNU)	adult patients with hemodialysis-dependent chronic kidney disease	approved by the FDA
Zoll Medical	second-generation TherOx System (SuperSaturated Oxygen SSO2) Therapy	reduction of heart muscle damage in “widowmaker” heart attack patients	approved by the FDA